Actively Recruiting
Clinical, Demographic, and Genetic Factors Linked to Response to Computer-assisted Cognitive Stimulation in Delirium Patients
Led by Institut Investigacio Sanitaria Pere Virgili · Updated on 2026-05-01
60
Participants Needed
1
Research Sites
17 weeks
Total Duration
On this page
Sponsors
I
Institut Investigacio Sanitaria Pere Virgili
Lead Sponsor
I
Institut Pere Mata
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating non-drug treatments for people aged 60 and older with delirium in a subacute care unit. The study aims to see if improving sleep schedules, mobility, and cognitive stimulation can help reduce delirium after one week. It also compares two groups: one receiving standard non-pharmacological care and the other getting additional computer-assisted cognitive therapy. The study will explore how personal factors like diseases, genetics, gender, age, and education affect delirium development, severity, and treatment response. Participants will be randomly assigned to one of two groups. One group will receive usual care focusing on orientation, cognitive stimulation, early mobility, and sleep-wake cycle restoration. The other group will receive the same care plus a twice-daily cognitive intervention using a tablet, guided by an occupational therapist, for up to 20 minutes per session over five working days. This intervention targets attention, orientation, and visuospatial abilities related to delirium symptoms. During the study, participants will be assessed at the start and after one week to measure changes in delirium severity, presence, and core symptoms according to DSM-5 criteria. Researchers will also monitor psychopharmacological treatments, functional independence, fall risk, walking ability, and clinical events. Adherence to non-pharmacological measures will be tracked from admission through the intervention week. The total study duration for each participant is one week after enrollment.
CONDITIONS
Brief Title
Computer-assisted Cognitive Stimulation Treatment for Delirium
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 60 years or older admitted to the subacute care center between 15 February and 15 October 2026
- Signed informed consent given by the patient or legal guardian if the patient cannot consent
You will not qualify if you...
- Patients receiving palliative end-of-life care at admission
- Individuals younger than 60 years old
- Severe visual or hearing impairment or aphasia preventing cognitive intervention
- Serious communication difficulties due to language barriers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 week
Participants receive either a computer-based cognitive stimulation intervention using a tablet twice daily for one week or usual non-pharmacological care focusing on cognitive stimulation, early mobility, and sleep-wake cycle restoration.
Daily interventions for 5 days (twice per day) with assessments at baseline and one week after enrollment
Trial Site Locations
Total: 1 location
1
Institut Pere Mata
Reus, Tarragona, Spain, 43206
Actively Recruiting
Research Team
E
Esteban Sepulveda-Ramos, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here